RTW Investments
VC Fund
New York, United States
RTW Investments is a VC fund in New York focused on Biotechnology and Health Care. RTW Investments makes investments in forward-thinking healthcare companies. It invests across the entire company lifecycle, including company creation, early-stage venture capital, alternative financing, and public company investments. The company is headquartered in New York with offices in London and Shanghai.
- Total investments:
- 147
- Last investment:
- Lead investor:
- 29%
- Fund size:
- $458M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries RTW Investments invests in
Stages RTW Investments invests in
Countries RTW Investments invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 79 (54%)
- Health Care 45 (31%)
- Therapeutics 35 (24%)
- Pharmaceutical 26 (18%)
- Medical 25 (17%)
Stage
- Post-IPO Equity 32 (22%)
- Series B 30 (20%)
- Series C 17 (12%)
- Series A 12 (8%)
- Series D 10 (7%)
Country
- United States 72 (49%)
- Switzerland 4 (3%)
- China 3 (2%)
- United Kingdom 3 (2%)
- Canada 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Lauren Lee
Research Analyst
|
Research Analyst | Total investments: 1 | Find email | |
Naveen Yalamanchi
Partner
|
Partner | Total investments: 5 | Find email | |
Robert Aurigema
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Sabera Loughran
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
Gaurav Shah
Entrepreneur in Residence
|
Entrepreneur in Residence | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $125M / Post-IPO Equity / Aug 06, 2026 | ||
| Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M / Post-IPO Equity / Aug 04, 2026 | ||
| Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M / Private Equity / Jul 22, 2026 | ||
| Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novelantibody-based immunotherapies.It was founded in 2019 and is based in Boston, Massachusetts. | $50M / Post-IPO Equity / Jun 30, 2026 | ||
| Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | ||
| Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technologicalbarriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates. | $300M / Post-IPO Equity / May 08, 2026 | ||
| Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | ||
| Amani Therapeutics is breaking down barriers with breakthrough technology to provide effective medicines for those suffering from significant psychiatric illnesses, restoring hope and stability and allowing them to live more fulfilling lives. | $25M / Series A / Mar 23, 2026 | ||
| Prolium is a biotechnology company, which specializes in providing breakthrough therapies to the patients with autoimmune diseases. | $50M / Series A / Mar 03, 2026 | ||
| Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostatecancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster. | $100M / Post-IPO Debt / Feb 19, 2026 | ||
| See all 147 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does RTW Investments invest in?
RTW Investments invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 147 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact RTW Investments?
Public channels for RTW Investments include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RTW Investments?
The team at RTW Investments includes Lauren Lee (Research Analyst), Naveen Yalamanchi (Partner) and Robert Aurigema (Chief Financial Officer), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
